NCT03889639: A reported trial by Sanofi
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03889639 |
|---|---|
| Title | A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 29, 2019 |
| Completion date | Jan. 2, 2020 |
| Required reporting date | Jan. 2, 2023, midnight |
| Actual reporting date | Dec. 7, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |